Oncotarget

Research Papers:

EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma

Lotte Hiddingh _, Bakhos A. Tannous, Jian Teng, Bas Tops, Judith Jeuken, Esther Hulleman, Sandra H. Boots-Sprenger, W. Peter Vandertop, David P. Noske, Gertjan J.L. Kaspers, Pieter Wesseling and Thomas Wurdinger

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:363-374. https://doi.org/10.18632/oncotarget.1620

Metrics: PDF 1907 views  |   HTML 2189 views  |   ?  


Abstract

Lotte Hiddingh1,2,3, Bakhos A. Tannous4, Jian Teng4, Bas Tops5, Judith Jeuken5,7, Esther Hulleman2,3, Sandra H. Boots-Sprenger5, W. Peter Vandertop1, David P. Noske1,3, Gertjan J.L. Kaspers2, Pieter Wesseling5,6, Thomas Wurdinger1,3,4

1 Department of Neurosurgery, VU University Medical Center, Amsterdam, The Netherlands

2 Department of Pediatric Oncology, VU University Medical Center, Amsterdam, The Netherlands

Neuro-oncology Research Group, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands

Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands

Department of Pathology, PAMM, Eindhoven, The Netherlands

Correspondence:

Thomas Wurdinger, email:

Keywords: Temozolomide resistance, glioblastoma, EFEMP1, γ-secretase, Notch, GSI

Received: November 20, 2013 Accepted: December 5, 2013 Published: December 7, 2013

Abstract

Glioblastoma is the most common malignant primary brain tumor. Temozolomide (TMZ) is the standard chemotherapeutic agent for this disease. However, intrinsic and acquired TMZ-resistance represents a major obstacle for this therapy. In order to identify factors involved in TMZ-resistance, we engineered different TMZ-resistant glioblastoma cell lines. Gene expression analysis demonstrated that EFEMP1, an extracellular matrix protein, is associated with TMZ-resistant phenotype. Silencing of EFEMP1 in glioblastoma cells resulted in decreased cell survival following TMZ treatment, whereas overexpression caused TMZ-resistance. EFEMP1 acts via multiple signaling pathways, including γ-secretase-mediated activation of the Notch pathway. We show that inhibition of γ-secretase by RO4929097 causes at least partial sensitization of glioblastoma cells to temozolomide in vitro and in vivo. In addition, we show that EFEMP1 expression levels correlate with survival in TMZ-treated glioblastoma patients. Altogether our results suggest EFEMP1 as a potential therapeutic target to overcome TMZ-resistance in glioblastoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1620